Best-selling Breville 2-in-1 dehumidifer and purifier for the home drops to lowest price yet at Amazon Australia
This small and compact device is designed to improve the air quality, reduce allergens and mold growth, particularly during the colder months when we tend to keep windows closed.
Perfect for placing in any room, bathroom or living space up to 50m2, the All Climate 2-in-1 can extract upto eight litres of moisture a day to help keep mould and dampness at bay.
You can even monitor and control the device from the couch using the Breville Home Connect app — there's even voice command available via Amazon Alexa & Google Home/Assistant.
Best yet, hundreds of Aussies are switching expensive dryer loads and opting for the 'laundry mode' on this device instead. Quick and efficient, it can dry your clothes in no time at all.
Currently reduced from $549 to just $439.20 — get in quick before this limited time deal expires.
8L in size, the Breville 2-in-1 Dehumidifer and Purifier is perfect for use during the winter to crack down on mould build up and stuffy air flow.
Designed for any room in the house, it works well in rooms up to 50m2 and can even assist with your laundry routine.
Simply use the Set & Forget SensAir System with your preferred humidity level, monitor the progress using the Breville Home Connect App, and the auto shut off will stop the device once the tank is full.
Thanks to the AntiViral HEPA-13 Purification, the All Climate 2-in-1 will help to draw in any airborne impurities, leaving your home feeling and smelling fresh.
Breville is a trusted homewares brand, with 94 per cent positive ratings from over 10 thousand customers who have purchased items at Amazon Australia.
Those who have got their hands on the Breville 2-in-1 Dehumidifer and Purifier says it is a 'great unit'.
'Looks, feels, and performs premium. Both dehumidifier and air purifying functions operate at a high quality, making the rooms feel fresh and clean,' one shopper commented.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Mercury
15 hours ago
- Mercury
Prescient advances cancer drug to unlock value
Prescient at critical stage of development with phase 2a trial underway for PTX-100 PTX-100 granted orphan drug and fast track designations by the US FDA, unlocking benefits Focus on advancing PTX-100 to potential registrational phase 2b trial to open commercial opportunities Special Report: Prescient Therapeutics has entered a critical stage where clinical data, regulatory support, and commercial potential begin to converge in a defining moment for a biotech company aiming to bring a new therapy to market. Prescient Therapeutics (ASX:PTX) is in phase 2a trial for its lead compound PTX-100 in patients with rare blood cancer relapsed/refractory Cutaneous T-Cell Lymphoma (r/r CTCL) with the potential for its phase 2b arm to be registrational. PTX-100 is a first-in-class compound with the ability to block an important cancer growth enzyme geranylgeranyl transferase-1 (GGT-1). It is believed to be the only GGT-1 inhibitor in the world in clinical development. The US Food and Drug Administration (FDA) has granted PTX-100 orphan drug designation (ODD) for all T-cell lymphomas and fast-track designation for treatment of adults with relapsed or refractory mycosis fungoides, the most common subtype of CTCL. Fast Track designation provides an expedited pathway to approval, with orphan drug designation offering market exclusivity for a period of seven years in the US. 'The aim is to improve the quality of life for people suffering from this terrible form of cancer and getting them the therapy they need as fast as possible,' CEO James McDonnell said. 'It's also an incentive for larger pharmaceuticals who are looking to add to their portfolio as the drug progresses through clinical development.' Potential regulatory trial for PTX-100 McDonnell is focused on getting PTX-100 through the phase 2a trial with the potential to make the second phase 2b arm a registration study. 'Fast Track designation opens a dialogue with the FDA for companies to provide ongoing trial updates, instead of a lengthy review at the end, to expedite therapies to patients who desperately need them,' he said. 'All we need to do is replicate the Phase 1b results, if the FDA agrees, they could potentially authorise Phase 2b as a registration study.' In the phase 1b trial PTX-100 delivered a 45% overall response rate and 64% clinical benefit in T-cell lymphoma, with just 4% serious side effects – well below the 30% benchmark. 'The first step now is to progress Phase 2a where we can define a dose which will also have some efficacy and safety data,' McDonnell said 'The registrational study means we are closer to approval and the momentum for PTX-100 really starts to accelerate and excitement grows on the commercial front.' Watch: James McDonnell discusses the first US site for the Phase 2a trial of PTX-100. Eyes on the commercialisation prize With over 27,000 new TCL cases every year, in eight major centres, PTX is targeting a market worth ~US$1.8 billion. Commercialisation of PTX-100 will become a key focus for Prescient if it advances to a registrational study, with all options on the table – including partnership, licensing, or taking the drug to market independently. 'We are confident in how PTX-100 could change the lives of thousands, we need the data now to back that confidence and provide the market a clear indication of the value the therapy can provide,' he said. 'PTX-100 is a first-in-class therapy with a unique mechanism of action which has shown very good results in the Phase 1b study. 'These results have exceeded our benchmarks and compare well to the available therapies on efficacy, duration and a safety perspective.' McDonnell said that Dimerix (ASX:DXB) was a great example of what a potential commercial pathway could look like for Prescient if Phase 2b became a registrational trial. Dimerix is advancing its lead candidate DMX-200 through the ACTION3 phase 3 trial for the rare kidney disease FSGS and has secured four regional licensing agreements to drive commercialisation. 'They were able to take orphan drug designated therapy DMX-200, which is currently in a phase 3 registration study, into significant licensing agreements worth approximately $1.4 billion,' he said. 'Dimerix have highlighted how these milestones, FDA designation and registrational study, can open commercialisation opportunities and drive value creation.' McDonnell said in biotech it often comes down to two questions with the first being: can you get a product to market? The second is: what kind of market is waiting at the end? Phase 2 trials usually provide clearer insights into a drug's potential, with data readouts serving as critical indicators that can drive value inflection points. Source: Prescient Therapeutics A series of upcoming catalyst Investors have plenty to watch out for in H2 CY25, with Prescient advancing its phase 2a study. 'We are excited for the release, once we reach 20 patients, of the initial data from the dose optimisation committee review, which will be a key event in determining the next steps for development of PTX-100,' McDonnell said. A share purchase plan aimed at raising $7 million to support Prescient's clinical program closed on July 25. 'There are several milestones we are looking to hit in the coming months and if we can potentially get that Phase 2b into a registration study we can start to shift our focus toward commercialisation opportunities,' McDonnell said. This article was developed in collaboration with Prescient Therapeutics, a Stockhead advertiser at the time of publishing. This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions. Originally published as Prescient focuses on advancing lead cancer drug toward pivotal trial
7NEWS
15 hours ago
- 7NEWS
Amazon's first colour Kindle arrives in Australia: Colorsoft offers ‘real paper' reading experiences
Calling all bookworms: Kindle's most anticipated launch to date has just arrived on Aussie shores — and you could be one of the first to get your hands on it. The Colorsoft Kindle, Amazon's first-ever colour device, is now available to purchase online, for as little as $399. More than just your average e-reader, Colorsoft offers an incredible display, allowing you to view images, book covers and even highlight text — all in colour. After launching back in 2024, Coloursoft has been declared as the 'best all-purpose e-reader' on the market, and shoppers are racing to get their hands on the newly-launched device at Amazon Australia. There's two sizes available, 16G ($399) and 32G ($449), meaning there's plenty of room to download and store all your favourite books from the Kindle store. Perfect for on-the-go reading without lugging around heavy books, get in quick to get your hands on the newly-launched Kindle device. Whether you're an avid reader or rely on a great book to keep you company on a daily commute, Kindle's new Colorsoft is changing the game when it comes to reading on the move. Lightweight, compact and easy to carry, this new arrival offers a high-contrast display that looks almost identical to reading a real paperback. 100 per cent distraction-free, with zero notifications or social media apps, it's great for delving into a great novel, with anti-glare tech to reduce eye stain. You can even read in the brightest light or late into the night with auto-adjusting features, perfect for flights or lounging in the sun. Not to mention that the new Kindle is waterproof, so you can you can even sit and read by the pool — or in the bath — without the worry. 'We're delighted to bring Kindle Colorsoft to our customers in Australia,' Jacqui Corbett, Amazon Devices Country Manager, Australia and New Zealand, tells Best Picks. 'This is a significant milestone for Kindle locally, offering readers the perfect blend of our beloved e-reader experience with high-contrast colour capabilities. 'Whether you're enjoying travel guides, children's books, graphic novels, or cookbooks, or simply want to personalise your reading with colourful highlights, Kindle Colorsoft delivers this, giving an enhanced reading experience anywhere, anytime.' To shop the Kindle Colorsoft, head to Amazon Australia her e. Shop Kindle Colorsoft Cases: Already got your hands on the new Kindle? Keep your device extra safe with a luxe-looking protective cover. Black, $69.95 Jade, $69.95 Raspberry, $69.95 Ruby, $99.95 Walnut, $99.95
7NEWS
5 days ago
- 7NEWS
Hair brand that sells one every minute launches two new products: People Haircare
Aussies are relying on one trusted brand to deliver salon-worthy results, for a fraction of the cost. People Haircare, available to buy at Coles, is home to everyday essentials for strands, all under $20. The hero product — a cult-favourite All-In-One treatment that sells one every minute — has had two new products join the shelf. The All-In-One Treatment Shampoo and All-In-One Treatment Conditioner ($16 each) work together to deeply clean, protect and repair after every use. Suitable for all hair types — including straight, wavy, curly and even coloured strands — this highly-anticipated duo can help to repair damage caused by heat styling, over-brushing, bleach or dye. Offering 10 benefits inside one routine, the products help to add shine, control frizz, protect and strengthen the strands. 'We launched the new All-In-One Treatment Shampoo and All-In-One Treatment Conditioner because we received overwhelming feedback from our customers who were looking for a shampoo and conditioner that prevented colour fade and was safe to use on colour-treated hair,' founder Katherine Ruiz tells Best Picks. 'These new products are the natural next step in expanding our All-In-One family. Our Leave-In Treatment has become a cult favourite - we sell one every minute across Australia. Now, we're excited to offer a shampoo and conditioner duo that not only strengthens and adds shine, but also protects against heat damage and colour fade,' she explains. The hero ingredients? Aloe vera juice and hydrolysed jojoba esters. Known for their deeply hydrating properties and ability to improve colour retention, you can spot visible results and softness after just a few washes. Founded by Katherine Ruiz in 2022, People Haircare was born from a desire to create high-performing, no-compromise haircare that's both affordable and accessible. Offering salon-quality formulas for supermarket prices, shoppers can pick up products for under $20 from their local Coles, in-store and online.
